1. Medtech Insight

Zimmer Biomet's ROSA ONE Spine System Wins FDA Nod; Other Solutions Presented At AAOS 2019

 
• By Marion Webb

US FDA cleared Zimmer Biomet's ROSA ONE spine application last Friday. During the recent Academy of Orthopedics Surgeons conference, Medtech Insight talked to Zimmer Biomet's general manager of Global Spine, Rebecca Whitney and Michelle Bianco, VP of Operations, to learn about the company's product pipeline and future strategy. 

AAOS sign

The highly anticipated US FDA clearance of Zimmer Biomet Holdings Inc.'s ROSA ONE spine application last Friday is welcome news for the company one week after its showcase at this year's American Academy of Orthopedic Surgeons' (AAOS) conference in Las Vegas.

At AAOS, Zimmer Biomet's booth drew surgeons' attention with the ROSA total knee arthroplasty (TKA) robotic system. Surgical robotics are...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

US FDA Unveils Plans To Consolidate Support Services

 
• By Derrick Gingery and Sue Sutter

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 
• By Brian Bossetta

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.